Abvc biopharma receives australian tga approval to initiate phase ii study of vitargus®

Fremont, ca, feb. 21, 2023 (globe newswire) -- via newmediawire -- abvc biopharma, inc. (nasdaq: abvc), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, cns, and ophthalmology, today announced that approval to initiate the phase ii study of its vitargus® medical device, in australia, was received from the australian therapeutic goods administration (tga) on february 9, 2023. vitargus is the first biodegradable vitreous substitute to facilitate retina reattachment surgery.
ABVC Ratings Summary
ABVC Quant Ranking